Clinical pharmacology strategies to support dose optimization of the recommended Phase 2 dose regimen of JNJ-5322, a BCMA×GPRC5D×CD3 trispecific antibody, in Relapsed/Refractory multiple myeloma
Year: 2025
Type: conference-abstract
Source: Blood
Institution: Johnson & Johnson (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417009509
Cites:
Cited by:
Related to: